CombiMatrix Increases Anticipated Net Proceeds from Public Offering to up to $12.2M | GenomeWeb

NEW YORK (GenomeWeb News) – CombiMatrix today raised the expected net proceeds from an intended public offering of its securities.

In a document filed with the US Securities and Exchange Commission, the company said that net proceeds from its proposed offering of 10,000 shares of Series D preferred stock is now estimated at up to $12.2 million, an increase from a previous estimate of up to $10.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.